Idera Pharmaceuticals, Inc. (NASDAQ:IDRA)

Idera currently has two big strikes against them. One is a lengthy string of pipeline failures related to both efficacy and safety issues, despite the appearance of having a powerful technical platform in the field of toll-like receptors. Despite their failures and destrutction of shareholder value, the company declined to bow out gracefully the way companies like Altus and Aryx did in similar circumstances. This brings us to the second strike, which is a heavy use of dilutive financing including preferred stock and ITM warrants. Although Yahoo Finance lists the current share count as 28M, my count of all shares including preferred and ITM warrants is 81M. That gives a true market cap of 60M, which is still puny but also undeserved given the low likelihood that the company won't dilute again before topline data from the phase II trial of IMO-8400 in psoriasis, which hasn't even begun yet. If that trial fails like so many of Idera's prior efforts, that's three strikes and out.

short

I do believe Dna and blood will be the future detection of cancer if its not already happening now I remember seeing something on the news about being able to detect cancer by blood maybe this company has a hold on this concept if so long

picks source: zzlangerhans
as of 12/7/2010, these were the 5 most underperformed designated "top picks" by zz. these are the 5 picks (out 7 top picks):
alny,idra,rtix,biod,bdsi
No due diligence performed, these are hail marys that atleast a couple may possibly be insane multi baggers potentially
Very risky.

rfaramir follow on zzlangerhan's follow on portefeuille's rec of his rec

Bravobevo

medical/biotech related picks - 4 buys / 4 sells
BUY:exel,idra,rtix,dcth
SELL:pbth,pcyc,vrtx,nbix

Technology platform with great potential.

stock picks with the potential of being doublers to multibaggers, yet risky, very risky and can go nearly to 0. hated by CAPs, but they have atleast 1 CAPs allstar that I like that has greenthumbed this one. These things have been beaten, and if 2 of 6 of em double, and another 2 don't even move, well it makes up if the last 2 go to zero n basically tank.
DMAN, FSLR, IDRA, ARQL, OSIR, MDVN

I simply used the screener to identify 1-star companies with the highest 52-week gain. The 1-star rating should mean they are bad companies and the 52-week gain should mean they are overpriced. We’ll see how it works!

New Hi

exiting patents needed for farmuecitical market will reflect son expanded orders and deman for larger supply.

It´s at it's most

Not a long-termie, because I'm not personally well into the stock and cannot tell whether they have something unique in their safes to take it out by Easter or not.
But I can tell a stock with such stats and such current price is to go down.

pharmaceuticals are always fluctuating up and down according to the seasons. summer is a down season.

Wall Street Pro Pick.

Hey - it's just a random pick from the top performers list. What do I know? (not much)

IDERA has cutting edge new science in the field of immunology. They have had their share of followers and detractors over the years, and survived through it all. They have a strong company plan now, good partners, and exciting therapies that will be used to combat aids, cancer, and other human maladies. Above all IDERA has always been an honest, intelligent company that had strived to make a difference in health and science.